You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥(01093.HK)曾急漲11% 針對新冠變異病毒株疫苗獲準在內地開展臨牀研究
阿思達克 04-04 10:20
美國經濟數據表現參差,但3月失業率降至逾兩年低,市場料聯儲局5月有逾七成機會加息半釐,美股上週五全面反覆高收升不足0.5%,但美股期貨全面回軟。亞太區股市今天窄幅個別發展。 恆指承上週五倒升勢,今早在新經濟股及碧桂園系等帶動高開187點或近0.9%,升幅擴至244點或1.1%報22,283遇壓,升幅曾收窄至84點,低見22,124獲承接,現報22,218,續升178點或0.8%,成交額275億元。 石藥(01093.HK)針對新冠變異病毒株自主研發mRNA疫苗獲準於內地開展臨牀研究。該股今早高開6.1%報9.38元,重越10天及50天後,升幅曾擴至11%高見9.79元遇壓,曾回順至9.32元獲承接,現報9.45,升6.9%,暫爲最強藍籌,成交已達2,539萬股。 石藥公佈,集團開發的新冠病毒mRNA疫苗「SYS6006」已獲國家藥品監督管理局批準,可於內地開展臨牀研究。SYS6006是針對新型冠變異病毒株自主研發的mRNA疫苗,根據毒株流行情況進行針對性的抗原突變設計,臨牀前研究表明,該產品對包含Omicron和Delta在內的當前主流突變毒株具有良好的免疫保護效力;通過體液免疫和細胞免疫對機體提供免疫保護並可產生記憶性B細胞,提供長效保護效力,也充份證明瞭該產品的安全性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account